Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
Collins has led the NIH under three presidents over more than 12 years.
A steady stream of spurious claims about COVID-19 vaccines and treatments swirl around the public consciousness.
Experts call for heightened precautions and better, more intensive therapies for COVID-19 patients with weakened immune systems.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
Plasma from recovered patients recently received a controversial FDA emergency use authorization as a potential treatment for COVID-19.
However, experts caution that data from randomized clinical trials are still lacking.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.